Summary
1.32 -0.08(-5.71%)05/09/2024
Akebia Therapeutics Inc. (AKBA)
Akebia Therapeutics Inc. (AKBA)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| -6.04 | 11.11 | -8.50 | -15.15 | 28.44 | 32.08 | -76.94 | -94.76 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 1.40 | |
| Open | 1.51 | |
| High | 1.56 | |
| Low | 1.38 | |
| Volume | 4,088,622 | |
| Change | -0.09 | |
| Change % | -6.04 | |
| Avg Volume (20 Days) | 2,728,808 | |
| Volume/Avg Volume (20 Days) Ratio | 1.50 | |
| 52 Week Range | 0.78 - 2.48 | |
| Price vs 52 Week High | -43.55% | |
| Price vs 52 Week Low | 79.49% | |
| Range | -7.28 | |
| Gap Up/Down | 0.01 | |
Fundamentals | ||
| Market Capitalization (Mln) | 279 | |
| EBIDTA | -6,868,000 | |
| PE Ratio | 0.0000 | |
| PEG Ratio | 0.0000 | |
| WallStreet Target Price | 5.00 | |
| Book Value | -0.1570 | |
| Earnings Per Share | -0.2800 | |
| EPS Estimate Current Quarter | -0.0400 | |
| EPS Estimate Next Quarter | -0.0900 | |
| EPS Estimate Current Year | -0.2900 | |
| EPS Estimate Next Year | -0.3200 | |
| Diluted EPS (TTM) | -0.2800 | |
| Revenues | ||
| Profit Marging | -0.2668 | |
| Operating Marging (TTM) | 0.0526 | |
| Return on asset (TTM) | -0.0931 | |
| Return on equity (TTM) | -5.5345 | |
| Revenue TTM | 194,623,008 | |
| Revenue per share TTM | 1.0380 | |
| Quarterly Revenue Growth (YOY) | 0.0070 | |
| Quarterly Earnings Growth (YOY) | 0.0000 | |
| Gross Profit (TTM) | 140,039,000 | |
| Dividends | ||
| Dividend Share | 0.0000 | |
| Dividend Yield | ||
| Valuations | ||
| Trailing PE | 0.0000 | |
| Forward PE | 0.0000 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 4.1167 | |
| Revenue Enterprise Value | 1.5973 | |
| EBITDA Enterprise Value | -76.8173 | |
| Shares | ||
| Shares Outstanding | 209,595,008 | |
| Shares Float | 190,197,962 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.07 | |
| Insider (%) | 1.93 | |
| Institutions (%) | 26.41 | |
05/09 09:10 EST - Zacks Investment Research
Akebia Therapeutics (AKBA) Reports Q1 Loss, Misses Revenue Estimates
Akebia Therapeutics (AKBA) came out with a quarterly loss of $0.09 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.14 per share a year ago.
Akebia Therapeutics (AKBA) Reports Q1 Loss, Misses Revenue Estimates
Akebia Therapeutics (AKBA) came out with a quarterly loss of $0.09 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.14 per share a year ago.
05/02 08:30 EST - PRNewsWire
Akebia Therapeutics to Report First Quarter 2024 Financial Results and Discuss Recent Business Highlights
Akebia to Host Conference Call on May 9, 2024, at 8:00 a.m. ET CAMBRIDGE, Mass.
Akebia Therapeutics to Report First Quarter 2024 Financial Results and Discuss Recent Business Highlights
Akebia to Host Conference Call on May 9, 2024, at 8:00 a.m. ET CAMBRIDGE, Mass.
04/03 09:11 EST - MarketBeat
Akebia Therapeutics Surges on FDA Approval for Anemia Treatment
Akebia Therapeutics Inc. NASDAQ: AKBA is a biopharmaceutical company specializing in developing treatments for chronic kidney diseases (CKD) and anemia management for patients with CKD. The medical sector company addresses unmet needs in the segment.
Akebia Therapeutics Surges on FDA Approval for Anemia Treatment
Akebia Therapeutics Inc. NASDAQ: AKBA is a biopharmaceutical company specializing in developing treatments for chronic kidney diseases (CKD) and anemia management for patients with CKD. The medical sector company addresses unmet needs in the segment.
03/28 08:11 EST - Zacks Investment Research
Akebia (AKBA) Up as Vafseo Gets FDA Nod for Anemia Due to CKD
Akebia (AKBA) gains during premarket hours on Mar 28 as its key product Vafseo (vadadustat) tablets receive FDA's approval for the treatment of anemia due to chronic kidney disease.
Akebia (AKBA) Up as Vafseo Gets FDA Nod for Anemia Due to CKD
Akebia (AKBA) gains during premarket hours on Mar 28 as its key product Vafseo (vadadustat) tablets receive FDA's approval for the treatment of anemia due to chronic kidney disease.
03/27 20:45 EST - Reuters
U.S. FDA approves Akebia's anemia drug
The U.S. Food and Drug Administration approved Akebia Therapeutics' drug to treat anemia caused by chronic kidney disease in dialysis patients, the drugmaker said on Wednesday.
U.S. FDA approves Akebia's anemia drug
The U.S. Food and Drug Administration approved Akebia Therapeutics' drug to treat anemia caused by chronic kidney disease in dialysis patients, the drugmaker said on Wednesday.
03/14 18:31 EST - Zacks Investment Research
Akebia Therapeutics (AKBA) Reports Break-Even Earnings for Q4
Akebia Therapeutics (AKBA) reported break-even quarterly earnings per share versus the Zacks Consensus Estimate of a loss of $0.05. This compares to loss of $0.04 per share a year ago.
Akebia Therapeutics (AKBA) Reports Break-Even Earnings for Q4
Akebia Therapeutics (AKBA) reported break-even quarterly earnings per share versus the Zacks Consensus Estimate of a loss of $0.05. This compares to loss of $0.04 per share a year ago.
03/11 17:05 EST - PRNewsWire
Akebia Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results
CAMBRIDGE, Mass. , March 11, 2024 /PRNewswire/ -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced plans to report fourth quarter and full year 2023 financial results on March 14, 2024.
Akebia Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results
CAMBRIDGE, Mass. , March 11, 2024 /PRNewswire/ -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced plans to report fourth quarter and full year 2023 financial results on March 14, 2024.
11/20 08:00 EST - PRNewsWire
Akebia Therapeutics to Present at Piper Sandler Healthcare Conference
CAMBRIDGE, Mass. , Nov. 20, 2023 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John Butler, Chief Executive Officer, will participate in a fireside chat at the Piper Sandler 35th Annual Healthcare Conference on Tuesday, November 28 th at 10:30 a.m.
Akebia Therapeutics to Present at Piper Sandler Healthcare Conference
CAMBRIDGE, Mass. , Nov. 20, 2023 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John Butler, Chief Executive Officer, will participate in a fireside chat at the Piper Sandler 35th Annual Healthcare Conference on Tuesday, November 28 th at 10:30 a.m.
10/26 11:20 EST - Zacks Investment Research
Akebia Therapeutics (AKBA) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
Akebia Therapeutics (AKBA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Akebia Therapeutics (AKBA) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
Akebia Therapeutics (AKBA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
08/28 15:12 EST - PennyStocks
3 Penny Stocks To Buy According To Analysts, Targets Up To 1,494%
If you're looking to gain an edge in the stock market today, you've got to have more than a list of penny stocks to watch. You need to understand how to use the wild volatility that has been created this year to your advantage.
3 Penny Stocks To Buy According To Analysts, Targets Up To 1,494%
If you're looking to gain an edge in the stock market today, you've got to have more than a list of penny stocks to watch. You need to understand how to use the wild volatility that has been created this year to your advantage.
08/25 11:16 EST - Zacks Investment Research
Akebia Therapeutics (AKBA) Reports Q2 Loss, Lags Revenue Estimates
Akebia Therapeutics (AKBA) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of a loss of $0.03. This compares to earnings of $0.23 per share a year ago.
Akebia Therapeutics (AKBA) Reports Q2 Loss, Lags Revenue Estimates
Akebia Therapeutics (AKBA) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of a loss of $0.03. This compares to earnings of $0.23 per share a year ago.
08/23 16:35 EST - PRNewsWire
Akebia Therapeutics to Report Second Quarter Financial Results and Discuss Recent Business Highlights
Akebia to Host Conference Call on August 25 th at 9:00 a.m. ET CAMBRIDGE, Mass.
Akebia Therapeutics to Report Second Quarter Financial Results and Discuss Recent Business Highlights
Akebia to Host Conference Call on August 25 th at 9:00 a.m. ET CAMBRIDGE, Mass.
07/19 07:45 EST - PRNewsWire
Akebia Therapeutics to Present at the H.C. Wainwright Kidney Conference
CAMBRIDGE, Mass. , July 19, 2023 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John Butler, Chief Executive Officer, will participate in a fireside chat at the H.C.
Akebia Therapeutics to Present at the H.C. Wainwright Kidney Conference
CAMBRIDGE, Mass. , July 19, 2023 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John Butler, Chief Executive Officer, will participate in a fireside chat at the H.C.
07/10 12:16 EST - PennyStocks
Best Stocks For Beginners with Little Money: How To Trade Penny Stocks
There are so many new traders and investors entering the stock market today. But if you're brand new, you might not have a lot of money to invest or don't want to risk a whole lot while you're learning how to trade.
Best Stocks For Beginners with Little Money: How To Trade Penny Stocks
There are so many new traders and investors entering the stock market today. But if you're brand new, you might not have a lot of money to invest or don't want to risk a whole lot while you're learning how to trade.
07/06 06:07 EST - InvestorPlace
Pocket Change, Big Gains: 3 Penny Stocks Ready to Boom
Investors seeking high-growth opportunities often turn their attention to penny stocks, which may have the potential to deliver substantial returns. The three potential high return penny stocks listed in the article possess the ingredients for explosive growth.
Pocket Change, Big Gains: 3 Penny Stocks Ready to Boom
Investors seeking high-growth opportunities often turn their attention to penny stocks, which may have the potential to deliver substantial returns. The three potential high return penny stocks listed in the article possess the ingredients for explosive growth.
06/19 10:58 EST - Zacks Investment Research
Is Akebia Therapeutics (AKBA) Stock Outpacing Its Medical Peers This Year?
Here is how Akebia Therapeutics (AKBA) and Haemonetics (HAE) have performed compared to their sector so far this year.
Is Akebia Therapeutics (AKBA) Stock Outpacing Its Medical Peers This Year?
Here is how Akebia Therapeutics (AKBA) and Haemonetics (HAE) have performed compared to their sector so far this year.
06/07 14:19 EST - PennyStocks
3 Hot Penny Stocks To Watch Before Next Week
Penny stocks typically trade for less than $5 and generally belong to small companies often overlooked by mainstream investors. Yet, for those willing to navigate the inherent risks, these cheap stocks can offer a world of potential.
3 Hot Penny Stocks To Watch Before Next Week
Penny stocks typically trade for less than $5 and generally belong to small companies often overlooked by mainstream investors. Yet, for those willing to navigate the inherent risks, these cheap stocks can offer a world of potential.
06/02 13:09 EST - Zacks Investment Research
All You Need to Know About Akebia Therapeutics (AKBA) Rating Upgrade to Buy
Akebia Therapeutics (AKBA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
All You Need to Know About Akebia Therapeutics (AKBA) Rating Upgrade to Buy
Akebia Therapeutics (AKBA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
06/02 10:53 EST - Zacks Investment Research
Are Medical Stocks Lagging Akebia Therapeutics (AKBA) This Year?
Here is how Akebia Therapeutics (AKBA) and Brookdale Senior Living (BKD) have performed compared to their sector so far this year.
Are Medical Stocks Lagging Akebia Therapeutics (AKBA) This Year?
Here is how Akebia Therapeutics (AKBA) and Brookdale Senior Living (BKD) have performed compared to their sector so far this year.
06/02 08:30 EST - PRNewsWire
Akebia Therapeutics to Present at Jefferies Healthcare Conference
CAMBRIDGE, Mass. , June 2, 2023 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John Butler, Chief Executive Officer, will present at the Jefferies Healthcare Conference on Wednesday, June 7, 2023 at 8:30 a.m.
Akebia Therapeutics to Present at Jefferies Healthcare Conference
CAMBRIDGE, Mass. , June 2, 2023 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John Butler, Chief Executive Officer, will present at the Jefferies Healthcare Conference on Wednesday, June 7, 2023 at 8:30 a.m.